Sanofi pauses phase 3 CIDP trial as riliprubart falls short of efficacy
Sanofi halted one phase 3 CIDP trial of riliprubart after an interim analysis showed insufficient efficacy and is evaluating whether to continue the second phase 3 study. The setback compounds a string of pipeline disappointments for the company and could reshape competition among CIDP therapies, including IVIg substitutes, with analysts previously eyeing riliprubart as a potential value driver in 2027.
